InvestorsHub Logo
Followers 249
Posts 29886
Boards Moderated 1
Alias Born 05/30/2012

Re: None

Tuesday, 10/22/2024 12:13:22 PM

Tuesday, October 22, 2024 12:13:22 PM

Post# of 233712
Amazing all the work done by our skeleton crew just since March of this year when Dr. Jay and FDA ended the hold. I suggest anyone interested in knowing more about leronlimab to go to the web site www.cytodyn.com and as always a good place to begin doing real due diligence. Upon such basic research it should be evident that the company is going to attract many collaborators in the upcoming 2025.

Our CRO, "Syneos Health has helped to develop or commercialize 92% of novel new drugs approved by the FDA in the last five years (2019-2023) and 91% of products granted marketing authorization by the European Medicines Agency." Now that is impressive and they are working to increase that with leronlimab.

Shouldn't be too much longer for this to begin: https://www.cancernetwork.com/view/fda-holds-meeting-for-leronlimab-rationale-dosing-in-ccr5-mss-mcrc

Lots of room for improvements and lots of room for leronlimab. "At present, only approximately 30% of cancer patients who receive pembrolizumab or nivolumab treatment for solid tumors will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in resistance to anti-PD-1 therapies as well as the spread of cancers."

As well, wondering how Dr. Sacha's presentation in Peru earlier this month was received. Nice to get out of the USA for some less biased real opinions based on science and not trash talk by competing pharmaceutical interests. India might be a great other place to start some trials. I expect something of this nature once a trial begins in USA. It will open many doors. The greatest investigators are those with independent analytical methods that look under every rock and search out compelling arguments of all kinds both pro and con. On this I predict from all I have read that leronlimab will one day reign supreme in this upcoming era of A.I..

$$CYDY$$ 2024 Excellent administration Dr. Jay.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News